In sum, loss of EFR3A (and/or EFR3B) expression inhibits oncogenic signaling in human KRAS-mutant pancreatic adenocarcinoma cells, which manifests as a reduction in transformed and tumorigenic growth. The gene discussed is EFR3A; the disease is pancreatic adenocarcinoma.